VolitionRx Limited announced the signing of a global supply agreement with a market leader in pet healthcare. Through Volition's supply agreement, the Company is engaged as a worldwide provider of the Nu.Q® Vet Cancer Test through its reference laboratory network for cancer indications in animal health. There are approximately 84 million pet dogs in the United States and just under 50% of dogs will have at least one veterinary care visit per annum which Volition believes will provide an incredible opportunity to screen those senior dogs (over 7 years) and breeds at risk of cancer from 4 years and upwards.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.66 USD | -4.21% | -10.81% | -7.95% |
05-14 | Transcript : VolitionRx Limited, Q1 2024 Earnings Call, May 14, 2024 | |
05-13 | VolitionRx Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.95% | 54.72M | |
-43.34% | 7.74B | |
+10.68% | 3.66B | |
-1.60% | 2.24B | |
-21.65% | 1.98B | |
-22.17% | 1.64B | |
+5.19% | 915M | |
+17.25% | 733M | |
-7.21% | 710M | |
-37.14% | 454M |
- Stock Market
- Equities
- VNRX Stock
- News VolitionRx Limited
- VolitionRx Limited Signs Global Supply Agreement for Nu.Q® Vet Cancer Test